RxDoctor Payments Data

Gilbert Fontenette, NP

Nurse Practitioner · Lafayette, LANPI 1225185564

Payments from drug & device makers

$1,957in general payments, 2019–2025

Across 97 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$459
  • Mylan Specialty L.p.$399
  • AstraZeneca$374
  • Getinge USA Sales, LLC$265
  • Regeneron Healthcare Solutions, Inc.$139
  • Boehringer Ingelheim$88
  • plus $232 from 6 others

What the payments were for

  • Food & beverage$1,957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,957 in reported general payments places this provider in the 75th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$15,382
Medicare patients
160
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$92,417
Breo ElliptaFluticasone/Vilanterol69$33,348
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$32,501
Spiriva RespimatTiotropium Bromide22$13,897
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$13,557
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$12,324
Incruse ElliptaUmeclidinium Bromide28$10,470
SymbicortBudesonide/Formoterol Fumarate23$8,323
Advair DiskusFluticasone Propion/Salmeterol13$3,463
Albuterol Sulfate HfaAlbuterol Sulfate133$3,246
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,964
Wixela InhubFluticasone Propion/Salmeterol29$2,136
Azelastine Hcl24$1,107
Roflumilast13$909
Fluticasone Propionate74$864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$459$149,792254 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$88$46,39865 claims
AstraZenecaBreztri Aerosphere, Symbicort$374$20,64740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →